Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-DLL4 Antibody-HRP (4O557) is a HRP-conjugated Rabbit antibody targeting DLL4. Anti-DLL4 Antibody-HRP (4O557) can be used in ELISA.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μg | $411 | 7-10 days |
Description | Anti-DLL4 Antibody-HRP (4O557) is a HRP-conjugated Rabbit antibody targeting DLL4. Anti-DLL4 Antibody-HRP (4O557) can be used in ELISA. |
Alias | δ-like 4 (Drosophila), δ-like 4, hδ2, hdelta2, delta-like 4 (Drosophila), Delta-like 4 |
Ig Type | Monoclonal Rabbit IgG |
Clone | 4O557 |
Reactivity | Human |
Application | ELISA |
Recommended Dose | ELISA: 0.1-1 μg/ml |
Antibody Type | Monoclonal |
Host Species | Rabbit |
Construction | This antibody was obtained from a rabbit immunized with purified, recombinant Human DLL4 / Delta4 extracellular domain (rh DLL4; TMPY-01321; NP_061947.1; Met 1-Pro 524), and conjugated with horseradish-peroxidase (HRP). |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in PBS |
Research Background | Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy. |
Conjucates | HRP |
Others Formats | Unconjugated |
Antibody Types Available | 2 |
Immunogen | Recombinant Human DLL4 protein (TMPY-01321) |
Antigen Species | Human |
Biology Area | Cancer Drug Targets, Notch Pathway |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. Keep away from direct sunlight. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.